Adimab Announces Antibody Discovery Collaboration with Boehringer Ingelheim

Adimab, LLC, the global leader in the discovery and optimization of fully human monoclonal and bispecific antibodies, today announced a multi-target partnership with Boehringer Ingelheim (BI). Under the terms of the agreement, Adimab will use its proprietary platform to discover and optimize antibodies against targets chosen by BI, who will have the rights to develop [...]

By | January 10th, 2018|Dartmouth Innovation|

Adimab Provides Year-End Update on 2017 Partnership Activities

Adimab, LLC, the global leader in the discovery and optimization of fully human monoclonal and bispecific antibodies, today announced that in 2017 it entered into agreements with seven new companies. In addition, Adimab announced the expansion of 12 of its current partnerships and the achievement of 49 technical and development milestones across multiple collaborations. Read [...]

By | January 8th, 2018|Dartmouth Innovation, New Hampshire, News|